Nurandociguat vs Praliciguat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Soluble guanylate cyclase · full Chronic Kidney Disease pipeline
Nurandociguat
Developed by Bayer
NCT06522997 · Phase 2 · completed
The study used random assignment, quadruple masking, and a placebo control with a large enrollment of 1,222 participants. Its primary endpoint was the surrogate measure of change in UACR, and the primary comparison cannot yet be judged because results are not posted.
No aligned efficacy figure on record for this race.
Praliciguat
Developed by Akebia Therapeutics under a licence from Cyclerion Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07268638 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Nurandociguat | Praliciguat |
|---|---|---|
| Kidney composite outcome | —Not reported | —Not reported |
| UACR, % change | —Not reported | —Not reported |
| eGFR slope | —Not reported | —Not reported |
| Haemoglobin, change | —Not reported | —Not reported |
Kidney composite outcome
- Nurandociguat
- —Not reported
- Praliciguat
- —Not reported
UACR, % change
- Nurandociguat
- —Not reported
- Praliciguat
- —Not reported
eGFR slope
- Nurandociguat
- —Not reported
- Praliciguat
- —Not reported
Haemoglobin, change
- Nurandociguat
- —Not reported
- Praliciguat
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Nurandociguat: no structured comparison results are available for Chronic Kidney Disease.
Praliciguat: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nurandociguat's landscape · Praliciguat's landscape